Pharmacogenomic test that predicts response to β2-agonists in adults with asthma is cost effective

Abstract

Background: Pharmacogenomic tests that predict which asthma patients are likely to respond to β2-agonists hold promise to improve care for asthma. Objective: To identify the clinical and economic circumstances under which a pharmacogenomic test that predicts response to β2-agonists might or might not be an appropriate, cost-effective option. Methods: We synthesized published data on clinical and economic outcomes in adults 18–35 to project 10-year costs, quality-adjusted life years and cost–effectiveness of pharmacogenomic testing for β2-agonist response. Results: Pharmacogenomic testing for β2-agonist response conferred a cost–effectiveness ratio of $13,700 per quality-adjusted life year gained compared with no testing. Conclusion: Pharmacogenomic testing for β2-agonist response in individuals with asthma is potentially cost effective and should be pursued by test developers.